Sibylle Loibl

Summary

Affiliation: German Breast Group
Country: Germany

Publications

  1. doi request reprint Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
    Gunter von Minckwitz
    German Breast Group, GBG ForschungsGmbH, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    Eur J Cancer 47:2273-81. 2011
  2. doi request reprint PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
    Sibylle Loibl
    Sibylle Loibl, Sana Klinikum, Offenbach Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu Isenburg Gunter von Minckwitz, Universitäts Frauenklinik Fariba Khandan, Agaplesion Markus Krankenhaus Clemens Heinrichs, OptiPath, Frankfurt Andreas Schneeweiss and Peter Sinn, Nationales Centrum fur Tumorerkrankungen, Heidelberg Stephan Paepke, Klinikum Rechts der Isar der Technischen Universitat, München Annika Lehmann, Berit Pfitzner, Judith L Lindner, and Carsten Denkert, Charité Universitätsmedizin Michael Untch, HELIOS Klinikum, Berlin Mahdi Rezai, Luisenkrankenhaus Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf Dirk M Zahm, SRH Waldklinikum, Gera Holger Eidtmann, Universitats Frauenklinik, Kiel Jens Huober, Universitats Frauenklinik, School of Health and Life Sciences
    J Clin Oncol 32:3212-20. 2014
  3. doi request reprint Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
    Sibylle Loibl
    German Breast Group, GBG Forschungs GmbH, Martin Behaim Strasse 12, 63263, Neu Isenburg, Germany
    Breast Cancer Res Treat 144:153-62. 2014
  4. pmc Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery
    Carsten Denkert
    Institute of Pathology, Charite Universitatsmedizin Berlin, 10117 Berlin, Germany
    Genome Med 4:37. 2012
  5. doi request reprint Treatment of breast cancer during pregnancy: an observational study
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    Lancet Oncol 13:887-96. 2012
  6. pmc Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
    Silvia Darb-Esfahani
    Institute of Pathology, Charite Universitatsmedizin Berlin, Chariteplatz 1, Berlin, 10117, Germany
    Breast Cancer Res 11:R69. 2009
  7. pmc Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
    Gunter von Minckwitz
    Dept of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
    Breast Cancer Res 10:R30. 2008
  8. doi request reprint Management of menopausal symptoms in breast cancer patients
    S Loibl
    German Breast Group, GBG Forschungs GmbH, Neu Isenburg, Germany
    Maturitas 68:148-54. 2011
  9. pmc Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    BMC Cancer 11:131. 2011
  10. doi request reprint Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    Support Care Cancer 19:1789-95. 2011

Detail Information

Publications47

  1. doi request reprint Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
    Gunter von Minckwitz
    German Breast Group, GBG ForschungsGmbH, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    Eur J Cancer 47:2273-81. 2011
    ..Here, we report the final analysis on overall survival...
  2. doi request reprint PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
    Sibylle Loibl
    Sibylle Loibl, Sana Klinikum, Offenbach Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu Isenburg Gunter von Minckwitz, Universitäts Frauenklinik Fariba Khandan, Agaplesion Markus Krankenhaus Clemens Heinrichs, OptiPath, Frankfurt Andreas Schneeweiss and Peter Sinn, Nationales Centrum fur Tumorerkrankungen, Heidelberg Stephan Paepke, Klinikum Rechts der Isar der Technischen Universitat, München Annika Lehmann, Berit Pfitzner, Judith L Lindner, and Carsten Denkert, Charité Universitätsmedizin Michael Untch, HELIOS Klinikum, Berlin Mahdi Rezai, Luisenkrankenhaus Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf Dirk M Zahm, SRH Waldklinikum, Gera Holger Eidtmann, Universitats Frauenklinik, Kiel Jens Huober, Universitats Frauenklinik, School of Health and Life Sciences
    J Clin Oncol 32:3212-20. 2014
    ....
  3. doi request reprint Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
    Sibylle Loibl
    German Breast Group, GBG Forschungs GmbH, Martin Behaim Strasse 12, 63263, Neu Isenburg, Germany
    Breast Cancer Res Treat 144:153-62. 2014
    ..The mastectomy rate was considerably high in ILC patients even after obtaining a pCR. We, therefore, suggest to offer NACT mainly to ILC patients with HR-negative tumours...
  4. pmc Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery
    Carsten Denkert
    Institute of Pathology, Charite Universitatsmedizin Berlin, 10117 Berlin, Germany
    Genome Med 4:37. 2012
    ..We predict an intensified use of metabolomic screens in clinical and preclinical studies focusing on the onset and progression of tumor development...
  5. doi request reprint Treatment of breast cancer during pregnancy: an observational study
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    Lancet Oncol 13:887-96. 2012
    ..Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether treatment for breast cancer during pregnancy is safe for both mother and child...
  6. pmc Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
    Silvia Darb-Esfahani
    Institute of Pathology, Charite Universitatsmedizin Berlin, Chariteplatz 1, Berlin, 10117, Germany
    Breast Cancer Res 11:R69. 2009
    ....
  7. pmc Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
    Gunter von Minckwitz
    Dept of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
    Breast Cancer Res 10:R30. 2008
    ..To investigate the predictive value of clinical and biological markers for a pathological complete remission after a preoperative dose-dense regimen of doxorubicin and docetaxel, with or without tamoxifen, in primary operable breast cancer...
  8. doi request reprint Management of menopausal symptoms in breast cancer patients
    S Loibl
    German Breast Group, GBG Forschungs GmbH, Neu Isenburg, Germany
    Maturitas 68:148-54. 2011
    ..Bisphosphonates reduce AI-induced bone resorption and can also increase disease-free and overall survival. Standard-dose endocrine and chemotherapy are associated with a decline in cognitive function...
  9. pmc Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    BMC Cancer 11:131. 2011
    ..Chemotherapy dose delay and/or reduction lower relative total dose intensity (RTDI) and may affect short- and long-term outcome of metastatic breast cancer (MBC) patients...
  10. doi request reprint Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    Support Care Cancer 19:1789-95. 2011
    ..Preliminary data suggest that pegfilgrastim given on day 4 (P4) might be superior to pegfilgrastim on day 2 (P2) in reducing grade 4 leucopenia...
  11. pmc Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
    Sibylle Loibl
    Department of Obstetrics and Gynecology, German Breast Group, Neu Isenburg, Germany
    Breast Cancer Res 10:R77. 2008
    ..Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane-based treatments because of a lack of data regarding toxicities of these compounds in older patients...
  12. doi request reprint Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
    Sibylle Loibl
    German Breast Group, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    Breast Cancer Res Treat 130:477-87. 2011
    ..Patients with an AR-negative tumour have a higher chance of achieving a pCR than those with an AR-positive one. But, patients with AR-positive tumours have a better survival especially if they did not achieve a pCR...
  13. doi request reprint Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial
    Sibylle Loibl
    German Breast Group, GBG Forschungs GmbH, Schleussnerstrasse 42, 63263, Neu Isenburg, Germany
    Cancer Chemother Pharmacol 63:953-8. 2009
    ..The aim of the RiTa trial is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule in anthracycline pre-treated metastatic breast cancer patients...
  14. doi request reprint Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:542-51. 2008
    ..We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non-cross-resistant regimen...
  15. doi request reprint Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
    Gunter von Minckwitz
    Universitäts Frauenklinik Frankfurt, German Breast Group Forschungs GmbH, Martin Behaim Strasse 12, 63263 Neu Isenburg, Germany
    J Clin Oncol 28:2015-23. 2010
    ..CONCLUSION Adding capecitabine to or prolonging duration of neoadjuvant EC plus docetaxel does not result in higher efficacy at surgery...
  16. doi request reprint Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
    Michael Untch
    Universitäts Frauenklinik Frankfurt, c o GBG Forschungs GmbH, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    J Clin Oncol 28:2024-31. 2010
    ..Combination of chemotherapy with trastuzumab should be considered when neoadjuvant treatment is given to patients with HER2-positive breast cancer...
  17. doi request reprint German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
    Gunter von Minckwitz
    Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu Isenburg Volker Möbus, Klinikum Frankfurt Hoechst, Frankfurt Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg Jens Huober, University Hospital Dusseldorf, Düsseldorf Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale Michael Untch, Helios Klinikum Berlin Buch, Berlin Christian Jackisch, Klinikum Offenbach, Offenbach Ingo J Diel, Schwerpunktpraxis für gynäkologische Onkologie, Mannheim Dirk Elling, Sana Klinikum Lichtenberg, Lichtenberg Bettina Conrad, Frauenklinik, Kassel Rolf Kreienberg, University Hospital Ulm, Ulm Volkmar Müller, University Hospital Hamburg, Hamburg Hans Joachim Lück, Praxis Hannover Stefanie Noeding, Nordstadt Krankenhaus, Hannover Ingo Bauerfeind, Frauenklinik Landshut, Landshut Michael Clemens, Klinikum Trier
    J Clin Oncol 31:3531-9. 2013
    ..Their effect in early breast cancer is controversial. Ibandronate is an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile. It therefore qualifies as potential agent for adjuvant use...
  18. doi request reprint Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
    Gunter von Minckwitz
    German Breast Group, c o GBG Forschungs GmbH, Martin Behaim Straße 12, 63263 Neu Isenburg, Germany
    J Clin Oncol 30:1796-804. 2012
    ..The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain...
  19. doi request reprint Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:552-62. 2008
    ..The relationship between extended chemotherapy and pathological complete response at surgery was investigated in a clinical trial...
  20. doi request reprint Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)
    Gunter von Minckwitz
    German Breast Group, c o GBG Forschungs GmbH, Martin Behaim Straße 12, 63263 Neu Isenburg, Germany
    Breast Cancer Res Treat 132:863-70. 2012
    ..However, complete eradication of adjacent DCIS is frequently observed. HER2-overexpression of the invasive ductal component decreases in a subset of tumors, which showed less tumor regression...
  21. doi request reprint Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
    Michael Untch
    HELIOS Klinikum, Berlin Buch, Berlin, Germany
    Lancet Oncol 13:135-44. 2012
    ..We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy...
  22. doi request reprint Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
    Gunter von Minckwitz
    Headquarters, German Breast Group, Neu Isenburg, Germany
    N Engl J Med 366:299-309. 2012
    ....
  23. doi request reprint Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    J Clin Oncol 29:2150-7. 2011
    ..Poly(adenosine diphosphate-ribose) polymerase (PARP) plays a key role in DNA repair and cellular stress response. Inhibitors of PARP show promising clinical activity in metastatic, triple-negative or BRCA-mutated breast cancer...
  24. doi request reprint Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
    Gunter von Minckwitz
    German Breast Group, c o GBG Forschungs GmbH, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    Breast Cancer Res Treat 125:145-56. 2011
    ....
  25. doi request reprint Response-guided neoadjuvant chemotherapy for breast cancer
    Gunter von Minckwitz
    Gunter von Minckwitz, Keyur Mehta, and Sibylle Loibl, Headquarters, German Breast Group, Neu Isenburg Jens Uwe Blohmer, St Gertrauden Krankenhaus, Berlin Serban Dan Costa, Universitats Frauenklinik, Magdeburg Carsten Denkert, Institute for Pathology, Charite, Berlin Holger Eidtmann, Universitäts Frauenklink, Kiel Wolfgang Eiermann and Claus Hanusch, Klinikum zum Roten Kreuz, Munich Bernd Gerber, Universitats Frauenklinik, Rostock Jörn Hilfrich, Henrietten Stiftung, Hanover Jens Huober, Universitats Frauenklinik Tubingen, Frauenklinik Christian Jakisch and Sibylle Loibl, Städtische Kliniken, Offenbach Gunter von Minckwitz, Universitats Frauenklinik, Frankfurt Sherko Kümmel, Klinikum Essen Mitte, Essen Stefan Paepke, Universitäts Frauenklinik rechts der Isar, Munich Andreas Schneeweiss, National Center for Tumor Diseases, Turkey
    J Clin Oncol 31:3623-30. 2013
    ..We investigated disease-free survival (DFS) and overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer...
  26. ncbi request reprint Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial
    Sibylle Loibl
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Ann Surg Oncol 13:1434-42. 2006
    ..Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery in patients with operable breast cancer. However, uncertainty remains regarding surgical procedures and predictors for successful breast-conserving surgery...
  27. doi request reprint The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Cancer Epidemiol Biomarkers Prev 20:2141-9. 2011
    ..Today, premenopausal women with increased risk for breast cancer have only limited nonsurgical options to reduce their risk...
  28. pmc Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial
    Yasmin Issa-Nummer
    German Breast Group, Neu Isenburg, Germany
    PLoS ONE 8:e79775. 2013
    ..The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT...
  29. ncbi request reprint A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93
    Manfred Kaufmann
    Universitats Frauenklinik, Theodor Stern Kai 7, 60596 Frankfurt, Germany
    Eur J Cancer 43:2351-8. 2007
    ..72-1.42, P=0.97) and 0.77 in HR-positive patients (95% CI 0.47-1.24, P=0.27). These results do not support the general use of goserelin after adjuvant chemotherapy in this group of premenopausal patients...
  30. doi request reprint Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany Universität Frankfurt, Frauenklinik, Frankfurt, Germany Electronic address
    Lancet Oncol 15:747-56. 2014
    ..We therefore aimed to assess the efficacy of the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer...
  31. doi request reprint Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study
    Gunter von Minckwitz
    GBG Forschungs GmbH, University of Frankfurt, Schleussnerstr 42, Neu Isenburg, Germany 63263
    J Clin Oncol 27:1999-2006. 2009
    ..In the German Breast Group 26/Breast International Group 03-05 trial, we investigated if trastuzumab treatment should be continued beyond progression...
  32. doi request reprint Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Clin Cancer Res 19:4521-31. 2013
    ..The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described...
  33. doi request reprint Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer
    Eugen Ruckhäberle
    Department of Obstetrics and Gynecology, Goethe University Frankfurt, Theodor Stern Kai 7, 60590, Frankfurter, Germany
    J Cancer Res Clin Oncol 139:1681-9. 2013
    ..Sphingolipids play important roles in apoptosis and cell proliferation. Sphingosine kinase 1 (SphK1) expression has a prognostic impact in primary breast cancer, but its predictive value is currently unknown...
  34. doi request reprint Lessons from the neoadjuvant setting on how best to choose adjuvant therapies
    Gunter von Minckwitz
    German Breast Group, Neu Isenhurg and Senologic Oncology, Luisenkrankenhaus Diisseldorf, Isenburg, Germany
    Breast 20:S142-5. 2011
    ..To review the recent literature on neoadjuvant treatment of breast cancer with respect to insights that might be used for better using systemic treatment in early breast cancer...
  35. doi request reprint Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without Carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
    Carsten Denkert
    Carsten Denkert, Bruno V Sinn, Berit M Pfitzner, Wolfgang D Schmitt, Silvia Darb Esfahan, Stephan Wienert, Frederick Klauschen, and Manfred Dietel, Charité Universitätsmedizin Berlin Carsten Denkert, German Cancer Consortium DKTK Peter Klare, Praxisklinik and Breast Center Jens Uwe Blohmer, St Gertrauden Krankenhaus and Charité Universitätsmedizin Micheal Untch, Helios Klinikum Berlin Buch, Berlin Gunter von Minckwitz, Stephan Gade, Keyur Mehta, and Sibylle Loibl, German Breast Group, Neu Isenburg Gunter von Minckwitz, Women s Hospital, University of Frankfurt Hans Tesch, Bethanien Hospital, Frankfurt Jan C Brase, Ralf Kronenwett, Karin Fisch, and Kristin Krappmann, Sividon Diagnostics, Cologne Ralf Kronenwett, Heinrich Heine University Dusseldorf, Düsseldorf Christian Schem, Christian Albrechts Universitat zu Kiel, Hermanos de San Juan de Dios
    J Clin Oncol 33:983-91. 2015
    ....
  36. ncbi request reprint Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    Manfred Kaufmann
    Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
    J Clin Oncol 24:1940-9. 2006
    ..As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined...
  37. ncbi request reprint Use of goserelin in the treatment of breast cancer
    Achim Rody
    Department of Obstetrics and Gynecology, JW Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Expert Rev Anticancer Ther 5:591-604. 2005
    ..Treatment decisions depend upon adjuvant endocrine pretreatment. Clinical data regarding ovarian protection by synchronous use of gonadotropin-releasing hormone in young breast cancer patients receiving chemotherapy are incoherent...
  38. doi request reprint Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
    Caterina Fontanella
    German Breast Group, Neu Isenburg, Germany
    Breast Cancer Res Treat 150:127-39. 2015
    ..001). Higher BMI was associated with lower pCR and a detrimental impact on survival. Normal weight patients had the best compliance to chemotherapy and received the highest taxane doses, which seems to be related with treatment outcomes. ..
  39. doi request reprint Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study
    Bernd Gerber
    University of Rostock, Rostock, Germany
    J Clin Oncol 29:2334-41. 2011
    ..We aimed to test the efficacy of ovarian function preservation with the LHRHa goserelin in patients with breast cancer...
  40. doi request reprint Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Curr Opin Obstet Gynecol 25:66-73. 2013
    ..Neoadjuvant treatment is used by an increased number of patients with breast cancer. This study reviews the current literature on how new research findings have impacted patients and treatment selection...
  41. ncbi request reprint What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?
    Gunter von Minckwitz
    German Breast Group GBG Forschungs GmbH, Neu Isenburg, Germany
    Oncology (Williston Park) 26:20-6. 2012
    ..Recent findings suggest pCR might not be the appropriate surrogate for long-term outcome in patients with hormone receptor-positive and HER2-positive tumors...
  42. ncbi request reprint Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1
    Achim Rody
    Department of Obstetrics and Gynecology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Cancer Res 13:1115-22. 2007
    ..One of those genes is plexin B1, a cell-surface receptor for the semaphorin Sema4D (CD 100). However, the biological role of plexin B1 in breast cancer is largely unknown...
  43. ncbi request reprint Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells
    Birgit Spänkuch-Schmitt
    Department of Obstetrics and Gynecology, School of Medicine, JW Goethe University, Theodor Stern Kai 7, 60596 Frankfurt, Germany
    Oncogene 21:3162-71. 2002
    ..Considerable antitumor activity was observed in vivo against A549 cells. This study suggests that antisense inhibitors targeted against PLK1 at well tolerated doses may be considered as a cancer therapeutic agent...
  44. doi request reprint Analysis of PIK3CA Mutations in Breast Cancer Subtypes
    Ruza Arsenic
    Institute of Pathology Charité, University Hospital Berlin Breast Cancer Center, DRK Klinikum Köpenick, Berlin German Breast Group, Neu Isenburg, Germany
    Diagn Mol Pathol 22:50-6. 2014
    ..PIK3CA mutation was found to be a frequent genetic change in all breast cancer subtypes but occurred with the highest rate in HR/HER2 tumors. Further studies are needed to validate the prognostic impact of different PIK3CA mutations. ..
  45. doi request reprint Predictive factors for response to neoadjuvant therapy in breast cancer
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    Oncol Res Treat 37:563-8. 2014
    ..Hormone-receptor status, proliferation markers, immune infiltrates and genetic alterations, such as germline BRCA and PIK3CA, can now be measured almost on a routine basis due to the decreased analysis costs...
  46. pmc Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
    Timo Faltus
    Department of Obstetrics and Gynecology, Medical School, J W Goethe University, Theodor Stern Kai 7, Frankfurt 60590, Germany
    Neoplasia 6:786-95. 2004
    ..Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as antiproliferative agents that display activity against neoplastic cells at very low doses...
  47. doi request reprint Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
    Miguel Martin
    Miguel Martín, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense Noelia Martinez, University Hospital Ramón y Cajal José Ángel Garcia Saenz, University Hospital Clínico San Carlos Eva Carrasco, Grupo Español de Investigación en Cáncer de Mama, Madrid Serafín Morales, Hospital Arnau de Vilanova de Lérida, Lérida Angel Guerrero, Valencian Institute of Oncology, Valencia Antonio Anton, University Hospital Miguel Servet, Zaragoza Montserrat Muñoz, University Hospital Clinic i Provincial Mireia Margeli, Hospital Universitario Germans Trias i Pujol, Barcelona Miguel Gil, Catalan Institute of Oncology, Hospitalet Manuel Ramos, Centro Oncologico de Galicia, La Coruña Juan R De la Haba Rodriguez, Instituto Maimonides de Investigación Biomédica de Córdoba IMIBIC Hospital Universitario Reina Sofía, Universidad de Cordoba, Cordoba, Spain Sibylle Loibl, Gunter von Minckwitz, and Keyur Mehta, German Breast Group, Neu Isenburg Sibylle Loibl, Gunter von Minckwitz, and Keyur Mehta, Sana Klinikum Offenbach, Offenbach Bahriye Aktas, Centre for Community Child Health Research
    J Clin Oncol 33:1045-52. 2015
    ..To test whether combining bevacizumab, an anti-vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence of resistance to ET...